Centralized procurement accelerates the process of survival of the fittest among enterprises. The company that wins the bid has a large market share, but at the cost of low-price sales of its products; the company that fails to win the bid has limited product market share, which is not conducive to the long-term development of the company and faces transformation. After centralized procurement screened out some companies, only pharmaceutical companies with real R&D capabilities remained. It is conducive to promoting the optimization and reorganization of the industry and promoting the scale and modernization of the industry.
The centralized procurement model of small profits but quick turnover is equivalent to a bloody battle for enterprises, causing the market value and profits of enterprises to shrink. However, exchanging quantity for price allows drugs to enter a broader consumer market. Drugs cover the whole country, which places higher requirements on product quality, production capacity supply and cost control of enterprises. Although it limits the development of pharmaceutical companies to a certain extent, it also promotes healthy competition in the market.
With the continuous and in-depth advancement of the national centralized purchasing normalization and institutionalization policy, it is the general trend that the price of generic drugs continues to decline and more types of drugs enter the centralized purchasing. The normalization of centralized purchasing not only tests a company’s pricing capabilities, but also tests its strategic decision-making and product layout capabilities. It is more important for pharmaceutical companies to adapt to the situation and actively innovate.
To lay out differentiated products, track selection is particularly important. For large pharmaceutical companies with R&D capabilities, they can take the path of R&D of innovative drugs. For some small and medium-sized pharmaceutical companies that do not have R&D capabilities, they can slowly grow and transform step by step by focusing on varieties that are urgently needed in clinical medicine and have low market competition.
Therefore, in summary, centralized procurement is beneficial to enterprises. If you still need to know the bid-winning information of the company, you can query it in the bid-winning database.
Yaozhi Data-Bid Winning Database